Abstract 485P
Background
We demonstrated LDCT lung cancer screening significant improved mortality benefit among Asian never-smokers (NS) compared to ever-smokers (ES). We compared age at diagnosis and characteristics of lung cancer between NS and ES.
Methods
Subgroup analysis were performed from the 14 studies from our previous meta-analysis which included both NS and ES participants and published by April 30, 2021. Our aims were to assess age at lung cancer diagnosis and histology between the 2 groups.
Results
Out of the 14 studies, 4 studies (729 patients/77568 ES, 155 patients/30834 NS) reported age at diagnosis. Eight studies reported histology of lung cancer per patient (5 studies, 207 patients/46,679 ES, 162 cases/35,771 NS) and lung cancer lesion (3 studies, 216 lesions in 192 patients/28898 ES, and 276 lesions in 241 patients/34857NS). Compared to lung cancer in ES, lung cancer in never smokers (LCINS) were diagnosed at younger age though mean year of diagnosis was significantly 1.98 years younger (95% CI -3.38 to – 0.58, I2 0.00%); had a higher proportion of adenocarcinoma (ADC), per patient: 96.58% vs. 69.70% with RR=1.16 (95%CI 0.98 – 1.38, I2 0.00%) and per lesions: 96.81% vs. 68.88% with RR=1.20 (95%CI 1.03 – 1.40, I2 0.00%). Conversely, a lower proportion of squamous cell carcinoma (SqCC), per patient case: 1.37% vs. 16.28% with RR=0.31 (95%CI 0.12 – 0.80, I2 12.41%), and per lung cancer lesions: 0% vs. 14.54% with RR=0.05 (95% CI 0.01 – 0.23, I2 0.00%)). There was a significantly higher RR of ADC over SqCC per patient case: 11.14 (95%CI 2.93 – 42.35, I2 52.10%) among NS vs. 2.49 (95%CI 1.20 – 5.18, I2 69.15%) among ES. The lung cancer lesion ADC/SqCC ratio was also significant per lesion: 73.21 (95%CI 14.83 – 361.54, I20.00%) among NS vs. 3.01 (95%CI 1.98 – 4.57, I2 22.37%) among ES. Two studies reported 3 interval cancers among 8530 ES and none among 9061 NS.
Conclusions
LCINS is predominantly ADC as expected with frequently seen multifocal adenocarcinoma. LCINS was diagnosed on average about 2 years younger in NS than ES suggesting that the age limit to initiate lung cancer screening in NS may be set lower compared to ES.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
M. Nagasaka: Financial Interests, Personal, Advisory Board: AstraZeneca, Caris Life Sciences, Daiichi Sankyo, Novartis, EMD Serono, Janssen, Lilly, Pfizer, Genentech, Mirati, Regeneron, Silverback; Financial Interests, Personal, Invited Speaker: Takeda, Blueprint; Financial Interests, Personal, Other, Travel: AnHeart. E. Shum: Financial Interests, Personal, Advisory Board: AstraZeneca, Genentech, Boehringer-Ingleheim, Janssen, Regeneron; Financial Interests, Institutional, Funding: Delfi Diagnostics. S.I. Ou: Financial Interests, Personal, Invited Speaker: Pfizer, Roche; Financial Interests, Personal, Advisory Board: JNJ/Janssen, Elevation Oncology, AnHeart Therapeutics; Financial Interests, Personal, Ownership Interest: MBrace Therapeutics, BlossomHill Therapeutics; Financial Interests, Institutional, Local PI: Pfizer, Mirati, JNJ/jassen, Merus, Revolution Medicine, Nuvalent. All other authors have declared no conflicts of interest.
Resources from the same session
320P - Treatment patterns and outcomes in Indian patients with advanced ovarian cancer: A single center experience
Presenter: Pushpendra Hirapara
Session: Poster Display
Resources:
Abstract
321P - Epidemiology and survival analysis of epithelial ovarian cancer: Results from comprehensive care center in north India
Presenter: Amit Badola
Session: Poster Display
Resources:
Abstract
322P - Evaluation of chemotherapy response score as a prognostic factor in advanced epithelial ovarian cancer: A prospective single centre study
Presenter: Upasana Palo
Session: Poster Display
Resources:
Abstract
323P - Platelet-to-lymphocyte ratio, neutrophil-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio as prognostic biomarkers in ovarian cancer among the Asian population: A meta-analysis
Presenter: Wikania Wira Wiguna I Gede
Session: Poster Display
Resources:
Abstract
324P - All-<italic>trans</italic> retinoic acid sensitizes ovarian cancer to niraparib by inhibiting ALDH1A1 activity
Presenter: Bingjie Mei
Session: Poster Display
Resources:
Abstract
325TiP - A phase III randomized controlled trial in primary stage three and four ovarian cancer after interval cytoreductive surgery (FOCUS/KOV-HIPEC-04)
Presenter: Myong Cheol Lim
Session: Poster Display
Resources:
Abstract
327TiP - A single arm phase II study of single agent pemetrexed in platinum resistant/refractory epithelial ovarian or primary peritoneal cancer
Presenter: Swasthik Parampalli
Session: Poster Display
Resources:
Abstract
337P - Demographic patterns and survival outcomes of patients with T and NK-cell lymphoma at the National Cancer Centre Singapore
Presenter: Mohamed Haniffa Bin Hasan Mohamed
Session: Poster Display
Resources:
Abstract
338P - Multicenter real-world study of advanced-stage non-nasal type NK/T cell lymphoma (NKTCL): Clinical features, treatment and prognosis
Presenter: Yuce Wei
Session: Poster Display
Resources:
Abstract
339P - A comparison of survival of patients with relapsed or refractory diffuse large B cell lymphoma undergoing allogeneic stem cell transplantation or receiving CAR-T therapy
Presenter: Kenta Hayashino
Session: Poster Display
Resources:
Abstract